Skip to content
Home
For Patients
Overview
PET/CT
FDG PET/CT
PSMA PET/CT
DOTATATE PET/CT
Amyloid PET/CT
Cardiac PET/CT
Whole & Total Body
SPECT/CT
Radioligand Therapy
Lu-177 PSMA Therapy
MRI
CT
Mammography
ABUS
Bone Density (DEXA)
Executive & Preventive
For Physicians
Research & Clinical Trials
International Patients
About
Overview
Leadership Team
Clinical & Research Investigators
Advisory Board
News
Contact
Home
For Patients
Overview
PET/CT
FDG PET/CT
PSMA PET/CT
DOTATATE PET/CT
Amyloid PET/CT
Cardiac PET/CT
Whole & Total Body
SPECT/CT
Radioligand Therapy
Lu-177 PSMA Therapy
MRI
CT
Mammography
ABUS
Bone Density (DEXA)
Executive & Preventive
For Physicians
Research & Clinical Trials
International Patients
About
Overview
Leadership Team
Clinical & Research Investigators
Advisory Board
News
Contact
NEWS
INITIO updates and comments on new studies.
Blog
Advantages of PSMA-PET imaging in prostate cancer care
Read More
Blog
68Ga-PSMA PET/CT Protocols May Differ for RP, BCR
Read More
Blog
PSMA PET/CT Lymph Node Staging Can Predict Prostate Cancer Surgery Outcomes
Read More
Blog
PSMA PET/CT may improve recurrent prostate cancer detection
Read More
Blog
PSA & PET Features to Select sLND Persons in Recurrent PCa
Read More
Blog
Nearly 30% of US Cancer Deaths Linked to Smoking
Read More
Blog
New Prostate Cancer Drug Canada
Read More
Blog
Health Canada Approves Illuccix® for Prostate Cancer Imaging
Read More
Blog
PET reveals visual brain pattern of long COVID
Read More
Blog
PET predicts long term response after CAR-T treatment for lymphoma
Read More
Blog
FDG and NaF PET/CT Predictive for Overall Survival in Genitourinary Malignancies
Read More
Blog
PET tracer may improve understanding of Alzheimer’s Disease
Read More
Page
1
Page
2
Page
3
Page
4
Close
Requisition Form
SCAN REQUISITION (GA-68 PSMA PET/CT) - Fillable Online
SCAN REQUISITION (FDG, DOTATATE AND NEURACEQ PET/CT) (DIAGNOSTIC CT)
THERAPY REQUISITION (LU-177 PSMA) - For Prostate Cancer
